Lilly rejoins KRAS race with swipe at Amgen and Mirati, plans 2021 clinical trial

Lilly rejoins KRAS race with swipe at Amgen and Mirati, plans 2021 clinical trial

Source: 
Fierce Biotech
snippet: 

Eli Lilly has rejoined the KRAS race months after toxicity forced it to dump its first candidate. The Big Pharma is set to enter phase 1 later this year with a new drug it compared favorably to rival assets developed by Amgen and Mirati Therapeutics.